FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBioCryst Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BCRX
BioCryst Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for BioCryst Pharmaceuticals, Inc. (BCRX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBCRX
BCRX
BioCryst Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BCRX
  1. Home
  2. Stocks
  3. BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

🇺🇸BCRX•NASDAQ

BioCryst Pharmaceuticals, Inc.

🇺🇸BCRX•NASDAQ
Market cap
$1.86B

Your view on BCRX

Mkt Cap
$1.86B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About BioCryst Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jon P. Stonehouse
Headquarters
4505 Emperor Boulevard, Durham, NC, US
Industry
Biotechnology
Sector
Healthcare
CEO
Jon P. Stonehouse
Headquarters
4505 Emperor Boulevard, Durham, NC, US
Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.

The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.

The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for BioCryst Pharmaceuticals, Inc.. Starting points for BioCryst Pharmaceuticals, Inc.: EPS -$1.41, beta 0.54 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for BioCryst Pharmaceuticals, Inc.. Trailing twelve-month EPS for BioCryst Pharmaceuticals, Inc. stands at -$1.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$19.00average of 3 firms, last 12 months
Current price—

Buy

Targets, low to high

$19.00

Low $11.00

Middle $17.00

High $29.00

Analyst ratings

7 firms, last 12 months
  • Strong Buy0
  • Buy5
  • Hold2
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.09$0.14−$2.31$0.53
Lowest estimate$0.02$0.12−$2.44$0.39
Highest estimate$0.14$0.14−$2.15$0.67
Number of analysts3245
A year ago$1.121−$2.981$1.211—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$165.24M$166.91M$718.73M$734.54M
Lowest estimate$156.85M$161.32M$669.03M$674.19M
Highest estimate$170.43M$171.39M$763.27M$783.88M
Number of analysts6277
A year ago$406.56M$156.41M$874.84M—
Growth vs a year ago−59.4%+6.7%−17.8%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for BioCryst Pharmaceuticals, Inc.. BioCryst Pharmaceuticals, Inc. has reported as a listed company since 1994. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BCRX15 companies · 8 funds
Compare BCRX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AVIRAtea Pharmaceuticals, Inc.HealthcareBiotechnology$318.0M
PHVSPharvaris N.V.HealthcareBiotechnology$2.2B
VIRVir Biotechnology, Inc.HealthcareBiotechnology$1.4B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
OXBOFOxford BioDynamics PlcHealthcareOTC$4.3M
OZYMFStrategic Partners A/SHealthcareOTC$3.7M
PAB.AXPatrys LimitedHealthcareASX—
PALIPalisade Bio, Inc.HealthcareNASDAQ$168.9M
PANCPanacos Pharmaceuticals, Inc.HealthcareOTC$5,367
PAR.AXParadigm Biopharmaceuticals LimitedHealthcareASX—
PARDPoniard Pharmaceuticals, Inc.HealthcareOTC$150
PASGPassage Bio, Inc.HealthcareNASDAQ$12.9M
PBIGFParadigm Biopharmaceuticals LimitedHealthcareOTC$87.9M
PBLAPanbela Therapeutics, Inc.HealthcareOTC$53,889
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.5B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$47,738
ETFs holding BioCryst Pharmaceuticals, Inc.
TickerFundFund assets% of the fund
XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.54%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
IWMiShares Russell 2000 ETF$76.6B in assets0.06%
VBVanguard Small-Cap ETF$76.9B in assets0.01%
PBEInvesco Biotechnology & Genome ETF$438M in assets2.12%
SBIOALPS Medical Breakthroughs ETF$187M in assets1.30%
BBPVirtus LifeSci Biotech Products ETF$133M in assets1.17%
FDLSInspire Fidelis Multi Factor ETF$255M in assets0.92%

Largest holders first, then the funds most concentrated in BCRX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold BioCryst Pharmaceuticals, Inc., and how their positions are changing. At a $1.86B market value, institutional positions materially move BioCryst Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by BioCryst Pharmaceuticals, Inc. executives and directors. Shares of BioCryst Pharmaceuticals, Inc. have traded between $6.00 and $11.31 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming BioCryst Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for BioCryst Pharmaceuticals, Inc.. Coverage tracks BioCryst Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of BioCryst Pharmaceuticals, Inc.

BCRX AnalysisFair
Past
2
Growth
5
Health
1
Profit
1
Value
1